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Interpretation and Multi-MPS Integration
J Yu1, NA Cilfone1, EM Large2, U Sarkar1, JS Wishnok1, SR Tannenbaum1,3, DJ Hughes2, DA Lauffenburger1, LG Griffith1,4,
CL Stokes5 and M Cirit1*
Our goal in developing Microphysiological Systems (MPS) technology is to provide an improved approach for more predictive
preclinical drug discovery via a highly integrated experimental/computational paradigm. Success will require quantitative
characterization of MPSs and mechanistic analysis of experimental findings sufficient to translate resulting insights from in
vitro to in vivo. We describe herein a systems pharmacology approach to MPS development and utilization that incorporates
more mechanistic detail than traditional pharmacokinetic/pharmacodynamic (PK/PD) models. A series of studies illustrates
diverse facets of our approach. First, we demonstrate two case studies: a PK data analysis and an inflammation
response––focused on a single MPS, the liver/immune MPS. Building on the single MPS modeling, a theoretical investigation
of a four-MPS interactome then provides a quantitative way to consider several pharmacological concepts such as
absorption, distribution, metabolism, and excretion in the design of multi-MPS interactome operation and experiments.
CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 585–594; doi:10.1002/psp4.12010; published online on 5 October 2015.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  Microphysiological Systems (MPS) development is an
emerging technology for predictive preclinical drug discovery approaches. Even though advanced in vitro MPS models
have been recently developed, quantitative understanding from such systems is still limited. • WHAT QUESTION DID
THIS STUDY ADDRESS?  How systems pharmacology approach can be used to advance experimental design and
data interpretation in microphysiological systems, and the development of a multi-MPS platform. • WHAT THIS STUDY
ADDS TO OUR KNOWLEDGE  We provide a methodology for this emerging field using systems biology and systems
pharmacology principles. The use of model-based data interpretation, experimental design, and system integration is
essential for such complex systems. Moreover, in comparison to traditional PK models, systems pharmacology models
provide more mechanistic knowledge of biological and pharmacological processes. • HOW THIS MIGHT CHANGE
CLINICAL PHARMACOLOGY AND THERAPEUTICS  Integration of system pharmacology and advances in tissue
engineering (microphysiological systems) may provide improved translation of preclinical findings to clinical outcomes.
Lack of efficacy and unpredicted toxicity continue to cause
high failure rates for drug candidates in clinical trials.1–3
The in vitro cell culture models and in vivo animal models
commonly used in preclinical studies provide limited infor-
mation relevant to human physiology.4,5 Therefore, new
approaches that are more easily translated to and predic-
tive of human clinical outcomes are desirable.6 A major
effort to improve preclinical models is the development of
“Microphysiological Systems” (MPSs) using engineered
human tissues that capture more physiological complexity
than standard cell cultures.7 An MPS typically contains
cocultures of human primary cells, 3D microenvironments,
and some degree of physiological mechanical and chemical
stimulation. Integration of multiple MPS constructs on a sin-
gle platform potentially enables pharmacologic and toxico-
logical studies of interacting human tissues and organ
systems, provided appropriate computational models can
be used to translate from in vitro to in vivo.
Seminal work by Shuler and colleagues beginning in the
early 1990s demonstrated that pharmacological communi-
cation between several organ system mimics could occur in
a multicompartmental bioreactor system.8 These interacting
organ systems could be miniaturized onto a 1-inch by 1-
inch silicon chip9 and interfaced with instrumentation to
measure physiological parameters.10 A parallel shift in
emphasis in the field of tissue engineering, from regenera-
tive medicine applications to in vitro models,11 has resulted
in numerous new complex models of liver, lung, gut, skin,
muscle, blood vessels, and other tissues.12–18 A substantial
push to further improve 3D models and integrate them to
improve translation of preclinical pharmacokinetics, efficacy,
and toxicology results from lab to clinic arose recently with
establishment in 2012 of the Microphysiological Systems
program by the United States Defense Advanced Research
Projects Agency, National Institutes of Health, and Food
and Drug Administration.19
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As the complexity of in vitro systems increases, experi-
mental design and data interpretation become more chal-
lenging. Successful use of single and multi-MPS platforms
for pharmacologic studies requires systematic characteriza-
tion of the relationships between drug exposure, MPS bio-
logical responses, and MPS–MPS interactions. While a
variety of pharmacokinetic/pharmacodynamic (PK/PD) mod-
els are used to characterize relationships between drug
kinetics and biological effects in in vivo models, the scope
of existing models is too limited for design of in vitro
systems and interpretation of data emerging from their
operation.20,21 Instead, computational models with greater
mechanistic detail capturing interrelated physical (e.g.,
inter-MPS flowrates) and biological (e.g., cytokine/growth
factor/hormone production and release) dynamics will be
needed to rationally design functional MPSs, select experi-
mental conditions, analyze and predict related human out-
comes. Moving from traditional empirical PK/PD models
towards more mechanistic models such as physiologically
based PK (PBPK) models and systems pharmacology mod-
els will not only provide greater power for predicting clinical
outcomes but will also offer more insight into the biological
systems of interest.6
Herein, we use systems pharmacology models for MPS
experimental design, data interpretation, and multi-MPS
platform integration. Data acquisition from the multi-MPS
platforms comprises measurements of soluble entities:
drugs and cell-produced molecules. Hence, our models
track exogenously administered soluble molecules (drugs,
medium components), modified molecules of exogenous
entities (metabolites), endogenously secreted biomolecules
(e.g., albumin, bile acids), and serological disease and PD
response markers (e.g., cytokines and growth factors), as
needed for a particular application. These models include
several pharmacological and physiological processes such
as absorption through epithelial barriers, molecular distribu-
tion between MPSs, and drug metabolism, excretion, and
protein binding. We first use these models to analyze drug
metabolism and disease response marker measurements
from a single MPS, the micro-perfused liver/immune
MPS,22,23 demonstrating the use of systems pharmacology
models for interpreting experimental results and guiding
experimental design. Building from such models of single
MPSs, the design and operational principles of a four-MPS
interactome are then theoretically investigated with the sys-
tems pharmacology approach.
MATERIALS AND METHODS
Liver/immune MPS experimental studies
The liver/immune MPS comprises a 3D coculture of
human hepatocytes and Kupffer cells, as previously
described in studies of drug metabolism, toxicity, and
aspects of the liver immune response.13,22–24 This MPS
was used herein to study the PK of hydrocortisone (HC)
as well as the liver inflammatory response to lipopolysac-
charides (LPSs). Details regarding the culture of liver/
immune MPS, HC, and cytokine quantification are in the
Supplementary Material.
Modeling and simulation
All modeling and simulation were performed in MATLAB
(R2014a, MathWorks, Natick, MA). MATLAB’s Genetic
Algorithm in Optimization Toolbox was used for parameter
estimation. MATLAB’s Statistics Toolbox was used to per-
form the two-way mixed design analysis of variance
(ANOVA). Global sensitivity analysis was performed using
Latin Hypercube Sampling (LHS) and Partial Rank Correla-
tion Coefficient (PRCC).
The traditional PK and mechanistic PK models for HC
and the model of inflammatory response to LPS stimulation
are detailed in the Supplementary Material.
A theoretical four-MPS interactome consisting of liver,
kidney, gut, and hypothetical PD MPS was computationally
modeled. The model includes oral drug absorption through
the gut epithelial barrier, plasma protein binding, unbound
drug metabolism in the liver MPS, drug excretion in the kid-
ney MPS, and drug transport between MPSs. The mixing
chamber is analogous to a blood compartment and allows
for the equivalent of intravenous drug administration and
media sampling. The inter-MPS flow rates are scaled based
on in vivo blood flow partitioning. Percentages of adult
human blood flow rates to kidney, portal vein, and hepatic
artery are 19%, 19%, and 6% of the cardiac output, respec-
tively.25 Thus, for this study the flow rates to kidney, gut,
hepatic artery, and the PD MPS in the four-MPS interac-
tome were specified as 40%, 40%, 10%, and 10% of the
mixing chamber output (Qmixing), with the last being appro-
priate to a highly vascularized organ like skin. This split
would be adjusted appropriately for any specified PD MPS.
Details of this model and the global sensitivity analysis are
in the Supplementary Material.26
RESULTS
Mechanistic pharmacokinetics of hydrocortisone in
liver/immune MPS
We first compare how a traditional PK model and a mecha-
nistic model provide different insights from in vitro systems.
Specifically, we study the effects of different concentrations
of human serum albumin (HSA) and cell culture periods on
HC PK in the liver/immune MPS. In humans, HC binds to
HSA and corticosteroid binding globulin (CBG) in blood,
leaving a small fraction unbound27; importantly, only
the unbound form functions biologically and can be
metabolized.28,29
In our experiments, HC concentration was measured in
the presence of low (1.25 mg/mL) and high (25 mg/mL)
HSA concentrations over 48 hours starting at culture day 3
or day 5 and the resulting PK was analyzed. Total HC
metabolism was modeled with a traditional PK model that
characterizes the disappearance of total HC as a single
metabolizable species (Supplementary Figure 1). For
comparison, HC metabolism was analyzed with a more
mechanistic model that accounted for HC binding to HSA,
in which only unbound HC was metabolized by hepato-
cytes. Equilibrium binding simulations (Supplementary
Figure 2), using published kinetic parameters30–32 for bind-
ing of HC and HSA, predicted that 5% and 53% of HC was
initially bound to HSA at 1.25 mg/mL and 25 mg/mL HSA,
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respectively. The metabolism rate constants of total HC
(kmetabolism,total) in the traditional PK model and free
(unbound) HC (kmetabolism,unbound) in the mechanistic PK
model were calculated by fitting the experimental HC kinetic
profiles (Figure 1, Supplementary Figure 1, and Table 1).
We investigated whether the calculated PK parameters
from each model were dependent on either HSA concentra-
tion or culture period using two-way mixed design ANOVA
(Supplementary Table 1). Data analysis by the traditional
PK model (i.e., the binding to HSA is not accounted for)
revealed that the apparent total HC metabolism rate con-
stant (kmetabolism,total) depends on both the cell culture
period (days 3–5 vs. days 5–7, P5 0.0012) and on the
HSA concentration (P5 0.039). In comparison, using the
mechanistic PK model the metabolic rate constant derived
for unbound HC (kmetabolism,unbound) is unaffected by HSA
concentration (P50.22), although it was still dependent on
cell culture period (P5 0.0082). No significant interaction
Table 1 HC pharmacokinetic parameters measured from the liver/immune MPS
Traditional (non-mechanistic) PK model kmetabolism,total
(mean 6 SEM, 31022/hr)
Mechanistic PK model kmetabolism,unbound
(mean 6 SEM, 31022/hr)
Low HSA High HSA Low HSA High HSA
Day 3-5 1.66 0.1 0.960.1 Day 3-5 1.660.1 1.8 60.2
Day 5-7 2.16 0.2 1.660.2 Day 5-7 2.260.2 2.86 0.3
Total HC metabolism rates (kmetabolism,total) were obtained with the traditional one-compartment PK model. Unbound HC metabolism rates (kmetabolism,unbound)
were obtained with the mechanistic model. Data and curve fits are shown in Figures 1 and S1.
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Figure 1 PK modeling of HC metabolism in the liver/immune MPS. HC PK data measured from the liver/immune MPS experiment on
culture day 3 to day 5 (a,b) and day 5 to day 7 (c,d) for low (a,c) and high (b,d) HSA concentrations were fitted to the mechanistic
model. Black lines correspond to total HC concentrations and red lines to free HC. Error bars and dashed lines represent SEM of
measured data and fitted curves, respectively (n5 3).
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between HSA concentration and cell culture period was
found in either model (Supplementary Table 1). Consider-
ing the effect of HSA concentration alone, the traditional
PK model resulted in a nonconstant kmetabolism,total as HSA
concentration varies. In contrast, the mechanistic PK analy-
sis had a constant value of kmetabolism,unbound as HSA con-
centration (and therefore initial HC bound/unbound ratio)
varies, suggesting that it can be used to study drug PK at
different plasma protein concentrations, e.g., in vivo studies.
Even so, the value of kmetabolism,unbound was sensitive to
MPS culture period. This suggests that MPS function over
time must be better understood to select appropriate MPS
experimental conditions that will potentially be translatable
to in vivo human PK.
Semimechanistic analysis of inflammatory response
biomarkers in the liver/immune MPS
Next we investigated the inflammatory response of the
liver/immune MPS to stimulation with repeated doses of
LPS using a semimechanistic model for production of two
inflammatory cytokines. LPS, secreted by Gram-negative
bacteria, induces cytokine release via binding of Toll-like
receptor 4 (TLR4) on Kupffer and other immune system
cells.33–36
An initial dose of LPS (1 mg/ml) induced a strong inflam-
matory response in the liver/immune MPS, with a transient
increase of secreted tumor necrosis factor-a (TNF-a) and
more sustained increase of interleukin-6 (IL-6). TNF-a and
IL-6 secretion was diminished after the removal of the
inflammatory stimulus (LPS) after 48 hours with complete
media change (Figure 2a,c). The repeated LPS dosing
every 48 hours induced inflammatory response only after
the first dose and failed to stimulate a significant response
for the subsequent doses (Figure 2b,d).
A semimechanistic model including LPS-binding of TLR4,
LPS-TLR4 complex internalization, TLR4 recycling, and
TNF-a and IL-6 production by Kupffer cells was used to
investigate possible mechanisms underlying these
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Figure 2 Modeling of the inflammatory responses in the liver/immune MPS. Net production of TNF-a appears transient (a) while that of
IL-6 is sustained (c). Subsequent doses of LPS fail to stimulate TNF-a (b) and IL-6 (d) secretion. The discontinuity at the 48-hour time-
point reflects a medium change. Symbols and error bars are measured data and SEM (n53). Solid lines are model fitted curves.
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observations (Supplementary Figure 3). The model reca-
pitulated the experimental observations, including desensiti-
zation to subsequent doses of LPS (Figure 2 and
Supplementary Figure 4). The model predicted that the
loss of cytokine response to a second high LPS dose
(1 mg/ml) was consistent with the saturation and internaliza-
tion of TLR4 receptors on the cell surface, coupled with a
relatively slow recycling rate of LPS-TLR4 complexes. In
comparison, simulations predicted that a more moderate
level of LPS (0.1 mg/mL) could induce a smaller but more
sustained response over multiple doses, while even lower
levels of LPS (<0.01 mg/mL) failed to elicit a substantial
inflammatory response (Figure 3). With further quantifica-
tion and characterization of the system, such simulations
using this data-driven modeling paradigm will be critical for
guiding experimental design, studying disease biology, and
could similarly be used for pharmaco- and toxicodynamic
studies.
Systems pharmacology-guided interactome design
In this section we focus on model-guided multi-MPS inter-
actome development, combining mechanistic modeling of
individual MPSs, as developed in the last two sections, with
PBPK modeling principles for the interactome. A four-MPS
interactome consisting of gut, liver, kidney, and PD MPSs
plus a mixing chamber was the focus because of its rele-
vance for comprehensive PK and PD studies (Figure 4).
The PD MPS is a placeholder for any MPS in which drug
PD is of interest, for instance, skin, cardiac muscle, carti-
lage, or brain.
We used our four-MPS systems pharmacology model to
investigate how biological and operational parameters gov-
ern the transport and fate of endogenous and exogenous
molecules in the four-MPS interactome. First, we consid-
ered the distribution and fate of a molecule produced endo-
genously by the liver MPS (e.g., bile acids, albumin, or
)b()a(
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Figure 3 A semimechanistic model of LPS-TLR4 binding, internalization, and trafficking predicts muting of inflammatory response on
repeated dosing. Simulated liver/immune MPS inflammatory responses to LPS doses of 1 mg/ml (red), 0.1 mg/ml (blue), 0.01 mg/ml
(black), and 0.001 mg/ml (cyan). LPS was added to the liver/immune MPS as a bolus dose at time 0 and again at the time of subse-
quent medium changes (48 and 96 hours), and the resulting temporal evolution of the concentrations of TNF-a (a) and IL-6 (b) were
simulated.
Figure 4 Model structure for the four-MPS interactome (Gut
MPS, Liver MPS, Kidney MPS, PD MPS, and mixing chamber).
In the four-MPS model, Qmixing is the sum of Qhepatic artery, Qgut,
Qkidney, and QPD.
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cytokines). We assumed a constant production rate in the
liver MPS and no elimination in any MPS. From a design
and operational view, an important consideration is how
quickly molecules will become “well-mixed” throughout the
system. The time required for the concentration of a chemi-
cal entity in the PD MPS to reach 80% of that in the mixing
chamber (tmixing,80) was used as the output function in
global sensitivity analysis to evaluate the effects of parame-
ters on concentration uniformity in the system.26 The analy-
sis indicated that tmixing,80 of an endogenously produced
molecule strongly depended on mixing chamber outlet flow
rate (Qmixing) and PD MPS media volume (VPD), while other
model parameters had minimal effects (Supplementary
Table 2). Figure 5a shows that as VPD increases, tmixing,80
also increases proportionally, as expected for dilution due
to added volume. In contrast, the effect of Qmixing on
tmixing,80 is nonlinear: increasing inter-MPS flow by raising
Qmixing from 0 to about 30–60 ml/day (depending on VPD)
strongly decreases tmixing,80, while further increases have
much less effect. Hence a Qmixing of about 30–60 ml/day
(given the other parameter values specified) is the highest
needed if uniform concentration in the system is the pri-
mary interest.
To guide studies of drug absorption, distribution, metabo-
lism, and excretion in the four-MPS interactome, we investi-
gated the effect of operational and biological parameters on
several measures important for PD. Specifically, the time
for the PD MPS and mixing chamber to become well-mixed
following drug administration, drug exposure, and the elimi-
nation of total drug in the platform. An oral drug was
assumed to be administered as a bolus to the gut MPS api-
cal side, absorbed to the basal side, and distributed to the
other MPSs (Figure 4). It can be metabolized by the liver
MPS and excreted by the kidney MPS only when unbound.
Sensitivity analysis for tmixing,80 relating uniformity of PD
MPS and mixing chamber indicates that Qmixing, VPD, and
drug intestinal permeability coefficient (P) are the primary
drivers (Supplementary Table 3). The effects of a range of
Qmixing and VPD for high (20 3 10
26 cm/s) and low (1 3
1026 cm/s) permeability coefficients are illustrated in
Figure 5b,c, respectively. Faster Qmixing and smaller VPD
result in shorter times to reach uniform concentration in the
system regardless of permeability. Low permeability drugs
take longer to reach uniformity than high permeability
drugs, however, for any Qmixing and VPD.
Pharmacodynamic effects of a drug depend not only on
its concentration but also on exposure of tissue to bioavail-
able (unbound) drug. Hence, we examined area under the
curve of unbound drug from 0 to 48 hours (AUC0-48) in the
PD MPS following administration to the apical side of the
gut MPS. Sensitivity analysis of AUC0-48 in the PD MPS
showed that the fraction of unbound drug (fu) had the
strongest modulating effect, while VPD, Qmixing, and P had
modest effects (Supplementary Table 3). Figure 5d
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Figure 5 Simulations of the four-MPS interactome. (a) tmixing,80 for an endogenously produced molecule as a function of Qmixing and
VPD. (b,c) tmixing,80 for a drug administered to the apical side of the gut (“oral administration”), as a function of Qmixing and VPD, for
cases of high intestinal drug permeability, ((b), P520 3 1026 cm/s) and low intestinal drug permeability ((c), P51 3 1026 cm/s).
(d) AUC0-48,PD for unbound drug as a function of Qmixing and VPD for orally administered drug. (e) AUC0-48,PD for unbound drug as func-
tion of fraction of drug unbound (fu) and P for orally administered drug. (f) Systemic total drug cleared percentage at 48 hours following
oral administration of drug as a function of fraction of drug unbound (fu) and hepatic metabolism rate constant (kmetabolism,liver).
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Figure 6 Simulations of drug concentration in each MPS plus mixing chamber of the four-MPS interactome for the oral drug adminis-
tration scenario and several combinations of parameter values; (red) high intestinal permeability coefficient P (20 3 1026 cm/s) with
high Qmixing (60 mL/day); (blue) high P (20 3 10
26 cm/s) with low Qmixing (5 mL/day); (magenta) low P (P5 1 3 10
26 cm/s) with high
Qmixing (60 mL/day).
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shows that exposure to unbound drug in the PD MPS can
be increased by increasing the operational parameters
Qmixing or decreasing VPD. However, exposure to unbound
drug is also strongly modulated by the biological parame-
ters fu and P (Figure 5e), over which we have little control.
Exposure to total drug (bound plus unbound) follows similar
trends, although the effect of fu is not nearly as strong as it
is for unbound drug exposure (results not shown).
Another important drug characteristic is its rate of disap-
pearance from the system. We characterized disappear-
ance by calculating the percentage of total drug cleared in
48 hours after drug administration to the apical compart-
ment of the gut. Unlike the parameters driving mixing
above, sensitivity analysis showed that the most influential
parameters driving percentage total drug cleared were
related to drug elimination and bioavailability (Supplemen-
tary Table 3). As expected, increasing either metabolism or
excretion increases system total drug cleared percentage,
as shown in Figure 5f for kmetabolism,liver. kexcretion,kidney has
a similar effect since the flow rates of both liver and kidney
MPS are similar (data not shown). Increasing fu also
increases clearance since only the unbound drug is avail-
able to be metabolized or excreted (Figure 5f). Likewise,
increasing gut permeability increases clearance since the
drug must be absorbed through the intestinal epithelia of
the gut MPS before it is cleared by MPSs.
Two parameters that strongly modulate system character-
istics across all output metrics studied above are the mixing
chamber outlet flowrate Qmixing and intestinal drug perme-
ability coefficient P. Plotting drug concentration kinetics in
the various MPSs as these parameters are varied provides
additional insights and guidance for experimental design.
Figure 6 shows this for a drug bolus applied to the apical
gut MPS at time50. As expected, drug concentration
decreases as it moves from source (apical gut, Figure 6)
to basal gut, liver, mixing chamber, and then all MPSs in
parallel, according to the flow pattern in Figure 4. A high
permeability drug transported with a high flowrate between
MPSs (red lines) results in the highest drug exposure, high-
est maximum concentration (Cmax), and earliest time to
maximum (tmax) in the downstream MPSs, compared to
either high P/low Qmixing (blue) or low P/high Qmixing
(magenta) conditions (low P/low Qmixing results in even
slower distribution between MPSs; not shown). Reducing
Qmixing or P individually has different consequences in dif-
ferent MPSs: reducing Qmixing only (blue) results in drug
accumulation in the basal gut, concentrations rising more
slowly in the liver MPS and mixing chamber, and even
more slowly in the kidney and the PD MPSs due to delays
in reaching there as well as further dilution in additional
media in those MPSs. In contrast, a low P drug with high
Qmixing (magenta) has a low but relatively similar concentra-
tion profile everywhere, since the drug enters the system
slowly but distributes quickly. Notably, reducing either Qmix-
ing or P alone results in similar concentration profiles in the
furthest downstream MPSs (kidney, PD).
The aggregate of all of these measures provides guid-
ance to experimental design and operation: for a given set
of MPS volumes, tmixing,80 indicates when the system is
close enough to uniform to sample from mixing chamber to
approximate the PD MPS concentration; AUC0-48 indicates
whether exposure will be appropriate to elicit desired PD
effects; percentage drug cleared at 48 hours indicates drug
PK; and the kinetic profiles provide detailed dynamic infor-
mation such as Cmax and tmax in each MPS which can
guide, for example, best sampling times.
DISCUSSION
Single MPS and multi-MPS interactomes are sufficiently
complex that the use of systems pharmacology models rep-
resenting the many physical, chemical, and biological char-
acteristics involved is crucial to MPS design, operation, and
data interpretation. The challenge for systems pharmacol-
ogy modeling is inclusion of enough mechanistic detail to
capture key observable system behaviors without including
so much that the models become unwieldy to simulate or
interpret, or have so many parameters they cannot be con-
strained by measurable data. With these considerations in
mind, we created a modeling framework to analyze data
from our liver/immune MPS as well as to investigate opera-
tional principles for a hypothetical four-MPS interactome.
Using this framework improves our understanding of biolog-
ical and pharmacological processes in the MPSs and lays
the groundwork for IVIVT.
We first demonstrated the use of our systems pharma-
cology framework to interpret experimental data from a sin-
gle MPS, the liver/immune MPS, for two conditions: drug
PK and disease response biomarkers. We demonstrated
that adding mechanistic considerations to a traditional PK
model could provide more detailed understanding of HC
metabolism. Hence, we aimed to develop strategies for
mechanistic data interpretation to obtain translational infor-
mation from our experiments. Due to experimental restric-
tions, it is generally not feasible to mimic in vivo processes
exactly and computational models are needed to translate
in vitro data to in vivo. In the HC case study, our experi-
mental setup had 47–95% unbound HC, whereas unbound
HC in human plasma is around 7.5%.27,37 Our mechanistic
analysis showed that the unbound HC metabolism rate
constant (kmetabolism,unbound) in the liver/immune MPS
remained unchanged for different HSA concentrations.
The mechanistic investigation of PK parameters, such as
kmetabolism,unbound, could potentially be used for IVIVT. To
predict in vivo pharmacokinetic properties of a given drug,
proper scaling and translation need to be performed by
considering several biological metrics (e.g., blood-to-tissue
and media-to-tissue ratios, cell numbers, organ size, and
plasma protein concentrations, etc.) for the MPSs and
human physiology. Moreover, our systems pharmacology
approach for data interpretation can be extended to more
detailed models for in-depth understanding of pharmacol-
ogy, which cannot be obtained by traditional PK models.
In our second liver/immune MPS case, we utilized a sys-
tems pharmacology model to interpret an inflammatory
response to LPS stimulation. Because of the complex
dynamics, a traditional PK/PD model would not capture,
much less explain, the results. A more mechanistic model
including ligand–receptor interactions and a minimal set of
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receptor dynamics (internalization and recycling) was able
to capture key observations, notably, differing kinetics of
two response biomarkers, TNF-a and IL-6, as well as the
lost response to a second high dose of LPS. Additional
simulations were used to investigate the liver/immune MPS
response to a range of LPS doses. The model predicts that
studies of chronic inflammation will require an intermediate
LPS dose that induces inflammation but does not cause
saturation and extensive downregulation of TLR4 receptors.
Next steps include experimental validation using a range of
LPS doses, with modification of the model as needed. At
that point the model will be well suited to guide design of
inflammation studies in the liver/immune MPS (e.g., selec-
tion of inflammatory stimulus dose level and timing; appro-
priate times to sample response biomarkers; effects of
modifying MPS design parameters).
A further interest is the use of multi-MPS platforms for
pharmacological studies, which requires careful considera-
tion of operational and biological parameters to attain
desired distribution and exposure of exogenous and endog-
enous molecules in the various compartments. Although
there are a few studies utilizing modeling and simulation for
in vitro organ interaction studies,38–40 no other study has
used systems pharmacology models to comprehensively
guide the design and operation of multi-MPS interactions.
While the models in our single liver/immune MPS investiga-
tions included mechanistic detail for both drug PK and
endogenous molecule production, we purposely eliminated
the latter in this initial four-MPS study to make the results
as general as possible. Such detail can be added for spe-
cific studies in the future.
Global sensitivity analysis along with examination of
kinetic concentration profiles provides guidance on what
drives important system outcomes. The practical utility of
these analyses will be beneficial for the multi-MPS system
developers and the experimental scientists and can best be
understood through specific examples. First, consider
studying the effects of a high permeability drug in the PD
MPS following bolus administration to the apical side of the
gut MPS (“oral administration”). Exposure to unbound drug
in the PD MPS will be maximized by a high flowrate
through the system (high Qmixing) and increasing fraction of
unbound drug in medium (high fu). A consequence of
increasing fu, however, will be faster clearance by liver
MPS and kidney MPS, so more frequent dosing may be
needed. Selection of sampling times can be guided by the
calculated tmixing,80 for the specified operating conditions,
along with the kinetic concentration profiles showing Cmax
and tmax in the PD MPS and other locations in the
interactome.
A contrasting example is the same scenario for a low
permeability drug. Now, high Qmixing has little effect on
exposure in the PD MPS, and so exposure will be maxi-
mized only through use of a high fu or increasing the dose
amount and/or frequency. High Qmixing will, however, drive a
uniform distribution, allowing for easier interpretation of
samples taken from the mixing chamber instead of a bio-
logical MPS, for example.
A third example is consideration of distribution of endoge-
nously produced molecules through a multi-MPS interac-
tome. For a given production rate, the concentration in the
downstream MPS of the production location will be maxi-
mized by increased inter-MPS flowrate and reduced
medium volume of the downstream MPS.
The selection of parameter values to use for any given
experiment will require additional simulations that weigh the
tradeoffs mentioned and selection of MPSs. Although our
conclusions are strongly related to the multi-MPS schema
considered, this study provides insights into approaches for
experimental design and interactome operation.
In conclusion, the use of systems pharmacology models
to analyze experimental results allows for a more mecha-
nistic understanding of both the pharmacological and
biological systems, which may lead to more predictive
in vitro–in vivo translation. Furthermore, systems pharma-
cology models provided guidance for designing multi-MPS
interactome studies in a quantitative manner. Both single
MPSs and multi-MPS interactomes will greatly benefit from
the use of quantitative, mechanistic models for their design,
operation, data interpretation, and translation to humans.
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